Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9184853rdf:typepubmed:Citationlld:pubmed
pubmed-article:9184853lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:9184853lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:9184853lifeskim:mentionsumls-concept:C0085112lld:lifeskim
pubmed-article:9184853lifeskim:mentionsumls-concept:C0007102lld:lifeskim
pubmed-article:9184853lifeskim:mentionsumls-concept:C0027627lld:lifeskim
pubmed-article:9184853lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:9184853lifeskim:mentionsumls-concept:C0079611lld:lifeskim
pubmed-article:9184853lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:9184853pubmed:issue5lld:pubmed
pubmed-article:9184853pubmed:dateCreated1997-9-4lld:pubmed
pubmed-article:9184853pubmed:abstractTextThe immunophenotype of HT29 human colon cancer cells implanted into severe combined immunodeficient mice was assessed in primary tumours and their metastases in the lungs using an indirect immunohistochemical method. After primary tumours were surgically removed, the metastases were given time to develop, thus paralleling the clinical situation. While vimentin was negative in both primary and secondary tumours, E-cadherin was present as membrane-bound labelling in the primary tumours only. Whereas the markers p53, MIB1, PCNA and CEA were consistently positive in both primary and metastatic tumours, CD44 variant 6 and CA125 were negative in metastases but positive in the primary tumours. There was a significant increase in the percentage of cells labelled for p53 in the primary tumours compared with the metastases. For the proliferation markers, there was no significant difference in labelling between primary tumours and metastases for MIB1. Of the cytokeratins examined, CK 20 gave the strongest and most consistent reaction in both primary and secondary tumours. The results indicate that, for certain immunohistochemical markers, results are the same in both primary tumours and metastases. Hence, in these cases, antigens that are expressed on the primary tumour as well as on the metastases can serve as target molecules for immunologically based forms of treatment of metastases.lld:pubmed
pubmed-article:9184853pubmed:languageenglld:pubmed
pubmed-article:9184853pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9184853pubmed:citationSubsetIMlld:pubmed
pubmed-article:9184853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9184853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9184853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9184853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9184853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9184853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9184853pubmed:statusMEDLINElld:pubmed
pubmed-article:9184853pubmed:monthMaylld:pubmed
pubmed-article:9184853pubmed:issn0018-2214lld:pubmed
pubmed-article:9184853pubmed:authorpubmed-author:MitchellB SBSlld:pubmed
pubmed-article:9184853pubmed:authorpubmed-author:SchumacherUUlld:pubmed
pubmed-article:9184853pubmed:authorpubmed-author:HornyH PHPlld:pubmed
pubmed-article:9184853pubmed:issnTypePrintlld:pubmed
pubmed-article:9184853pubmed:volume29lld:pubmed
pubmed-article:9184853pubmed:ownerNLMlld:pubmed
pubmed-article:9184853pubmed:authorsCompleteYlld:pubmed
pubmed-article:9184853pubmed:pagination393-9lld:pubmed
pubmed-article:9184853pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:meshHeadingpubmed-meshheading:9184853-...lld:pubmed
pubmed-article:9184853pubmed:year1997lld:pubmed
pubmed-article:9184853pubmed:articleTitleImmunophenotyping of human HT29 colon cancer cell primary tumours and their metastases in severe combined immunodeficient mice.lld:pubmed
pubmed-article:9184853pubmed:affiliationAnglo-European College of Chiropractic, Bournemouth, UK.lld:pubmed
pubmed-article:9184853pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9184853pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9184853lld:pubmed